This study will provide continuing availability to tazemetostat as a single agent to subjects who have completed their participation in a previous study.
This trial is treating multiple types of cancer including Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Malignant Rhabdoid Tumors (MRT), Rhabdoid Tumors of the Kidney (RTK), Atypical Teratoid Rhabdoid Tumors (ATRT), Synovial Sarcoma, Epitheliod Sarcoma or Mesothelioma.
This is a systemic therapy rollover.
You may be able to join this trial if:
- You have had a certain type of treatment or surgical procedure.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.